Literature DB >> 30016493

Oral squamous carcinoma cells promote macrophage polarization in an MIF-dependent manner.

M Barbosa de Souza Rizzo1,2,3, M Brasilino de Carvalho1,2, E J Kim3, B E Rendon3, J T Noe3,4, A Darlene Wise3,5, R A Mitchell3,4,5,6.   

Abstract

BACKGROUND: Tumor-associated macrophages (TAMs) are important determinants of intratumoral immune evasion, neoangiogenesis, extracellular matrix remodeling and dysregulated tumor cell proliferation. Our prior studies revealed that macrophage-derived, but not tumor cell-derived, macrophage migration inhibitory factor (MIF), is an important determinant of TAM alternative activation and M2 polarization. AIM: Because MIF is historically thought to initiate signaling via a receptor-dependent, outside-in mode of action, we wished to investigate the specific contributions of tumor-derived vs. macrophage-derived MIF to M2 marker expression during macrophage polarization.
DESIGN: Murine oral squamous cell-carcinoma cells (SCCVII) were co-cultured with either the RAW 264.7 mouse macrophage cell line or mouse primary bone marrow-derived macrophages in the context of MIF genetic loss/inhibition individually or in combination each cell type.
METHODS: Twelve well Transwell plates were used to co-culture SCCVII cells and RAW 264.7, MIF+/+ or MIF-/- macrophages treated with/without the small molecule MIF inhibitor, 4-iodo-6-phenylpyrimidine and incubated in the presence or absence of interleukin (IL-4) for 48 h. Macrophages were analyzed by quantitative real-time polymerase chain reaction and/or immunoblotting for relative macrophage polarization marker expression.
RESULTS: IL-4 treatment synergizes with SCCVII co-culture in inducing the expression of macrophage M2 markers and loss or inhibition of macrophage-derived MIF significantly reduces both IL-4 alone and IL-4/SCCVII co-culture-induced macrophage M2 marker expression.
CONCLUSION: These studies identify an important and dominant requirement for macrophage MIF in maximal Th2-cytokine and oral squamous carcinoma cell-induced macrophage polarization and M2 marker expression.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30016493      PMCID: PMC6217709          DOI: 10.1093/qjmed/hcy163

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  34 in total

1.  STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion.

Authors:  Sergei Kusmartsev; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

2.  Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response.

Authors:  Robert A Mitchell; Hong Liao; Jason Chesney; Gunter Fingerle-Rowson; John Baugh; John David; Richard Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

3.  Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor.

Authors:  A V Sampey; P H Hall; R A Mitchell; C N Metz; E F Morand
Journal:  Arthritis Rheum       Date:  2001-06

4.  Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells.

Authors:  M Munder; K Eichmann; J M Morán; F Centeno; G Soler; M Modolell
Journal:  J Immunol       Date:  1999-10-01       Impact factor: 5.422

5.  Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1.

Authors:  R Kleemann; A Hausser; G Geiger; R Mischke; A Burger-Kentischer; O Flieger; F J Johannes; T Roger; T Calandra; A Kapurniotu; M Grell; D Finkelmeier; H Brunner; J Bernhagen
Journal:  Nature       Date:  2000-11-09       Impact factor: 49.962

6.  CD163-Positive Macrophages Within the Tumor Stroma Are Associated With Lymphangiogenesis and Lymph Node Metastasis in Oral Squamous Cell Carcinoma.

Authors:  Yuko Yamagata; Hirofumi Tomioka; Kei Sakamoto; Kiyoshi Sato; Hiroyuki Harada; Tohru Ikeda; Kou Kayamori
Journal:  J Oral Maxillofac Surg       Date:  2017-03-18       Impact factor: 1.895

7.  Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening.

Authors:  Zoe Cournia; Lin Leng; Sunilkumar Gandavadi; Xin Du; Richard Bucala; William L Jorgensen
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

8.  MIF as a glucocorticoid-induced modulator of cytokine production.

Authors:  T Calandra; J Bernhagen; C N Metz; L A Spiegel; M Bacher; T Donnelly; A Cerami; R Bucala
Journal:  Nature       Date:  1995-09-07       Impact factor: 49.962

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor.

Authors:  T Calandra; J Bernhagen; R A Mitchell; R Bucala
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

View more
  9 in total

1.  Identification and validation of an immunological microenvironment signature and prediction model for epstein-barr virus positive lymphoma: Implications for immunotherapy.

Authors:  Chenjiao Yao; Ruoyao Xu; Qianyuan Li; Sheng Xiao; Min Hu; Linyong Xu; Quan Zhuang
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

2.  Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells.

Authors:  Yan Guo; Xiaoqin Lu; Yao Chen; Beatriz Rendon; Robert A Mitchell; Miriam Cuatrecasas; Marlies Cortés; Antonio Postigo; Yongqing Liu; Douglas C Dean
Journal:  Sci Adv       Date:  2021-05-21       Impact factor: 14.136

Review 3.  MIF-Dependent Control of Tumor Immunity.

Authors:  Jordan T Noe; Robert A Mitchell
Journal:  Front Immunol       Date:  2020-11-25       Impact factor: 7.561

4.  Exosomal MIF Derived From Nasopharyngeal Carcinoma Promotes Metastasis by Repressing Ferroptosis of Macrophages.

Authors:  Wenhui Chen; Fan Zuo; Kaiwen Zhang; Tian Xia; Wei Lei; Zixiang Zhang; Lili Bao; Yiwen You
Journal:  Front Cell Dev Biol       Date:  2021-12-31

5.  Exosomes from adipose-derived stem cells regulate M1/M2 macrophage phenotypic polarization to promote bone healing via miR-451a/MIF.

Authors:  Rui Li; Dize Li; Huanan Wang; Kaiwen Chen; Si Wang; Jie Xu; Ping Ji
Journal:  Stem Cell Res Ther       Date:  2022-04-08       Impact factor: 6.832

Review 6.  Mesenchymal Stem Cell-Derived Extracellular Vesicles for Bone Defect Repair.

Authors:  Dongxue Wang; Hong Cao; Weizhong Hua; Lu Gao; Yu Yuan; Xuchang Zhou; Zhipeng Zeng
Journal:  Membranes (Basel)       Date:  2022-07-19

7.  PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages.

Authors:  Lu Wang; Shuangshuang Li; Huanhua Luo; Qi Lu; Shuwen Yu
Journal:  J Exp Clin Cancer Res       Date:  2022-10-14

8.  Single-Cell Transcriptome Analysis Reveals Different Immune Signatures in HPV- and HPV + Driven Human Head and Neck Squamous Cell Carcinoma.

Authors:  Simin Li; Yang Wang; Rui Sun; Debora Franceschi; Hongying Pan; Chenxuan Wei; Anthony Chukwunonso Ogbuehi; Bernd Lethaus; Vuk Savkovic; Sebastian Gaus; Rüdiger Zimmerer; Dirk Ziebolz; Gerhard Schmalz; Xiao Jiang
Journal:  J Immunol Res       Date:  2022-09-16       Impact factor: 4.493

9.  Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration.

Authors:  Sho Kawaguchi; Kenta Kawahara; Yukio Fujiwara; Koji Ohnishi; Cheng Pan; Hiromu Yano; Akiyuki Hirosue; Masashi Nagata; Masatoshi Hirayama; Junki Sakata; Hikaru Nakashima; Hidetaka Arita; Keisuke Yamana; Shunsuke Gohara; Yuka Nagao; Manabu Maeshiro; Asuka Iwamoto; Mayumi Hirayama; Ryoji Yoshida; Yoshihiro Komohara; Hideki Nakayama
Journal:  Cancer Immunol Immunother       Date:  2022-01-19       Impact factor: 6.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.